CNS-Selective Autophagy Compounds for Brain Tissue Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more selective autophagy inducers that can effectively treat and prevent diseases involving the central nervous system (CNS) by inducing and/or stimulating autophagy, particularly in conditions such as cancer, age-related diseases, and viral infections.
Innovation Solution
Development of compounds according to Formula (I) or their physiologically acceptable salts, solvates, and hydrates, which are highly effective autophagy inducers, exhibiting a preferential concentration ratio of 2:1 in the CNS to peripheral tissues, enhancing autophagy induction in CNS-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing autophagy inducers (e.g., Chloroquine, Hydroxychloroquine) are used for cancer treatment, then autophagy is inhibited in tumor cells, but these compounds lack selectivity for CNS-related diseases and do not effectively induce autophagy in the central nervous system
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I) that exhibit preferential accumulation in CNS tissues. The compounds contain heteroaryl groups and specific substituents that enable selective interaction with CNS cellular targets, particularly in neurons and glial cells, while minimizing activity in peripheral tissues. This structural design provides the desired selectivity for CNS-related diseases.
Solution Approach 2:
The patent employs parameter changes by modifying molecular properties such as lipophilicity, molecular weight, and heteroatom composition to optimize blood-brain barrier penetration. The compounds are designed with specific logP values and molecular characteristics that enhance CNS distribution while maintaining autophagy-inducing activity. This allows the compounds to achieve both brain penetration and selective CNS action.
2Quantity of substance
If autophagy is induced systemically to treat various diseases, then autophagy is stimulated throughout the body, but the compounds do not achieve sufficient concentration in the CNS to effectively treat neurological conditions
Solution Approach 1:
The patent achieves local quality by designing compounds that selectively accumulate in CNS tissues through specific molecular interactions with brain endothelial cells and transport mechanisms. The compounds exhibit enhanced permeability and retention in the brain, achieving concentrations 2-10 times higher than peripheral tissues at equivalent systemic doses, thereby optimizing CNS exposure while maintaining reasonable systemic pharmacokinetics.
3Adaptability or versatility
If broad-spectrum autophagy inducers are used, then multiple disease types may be treated, but the compounds cannot effectively distinguish between different pathological conditions requiring autophagy modulation
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features that enable selective targeting of pathological processes in different diseases. The heteroaryl groups and substituents in Formula I compounds can interact with disease-specific proteins and cellular pathways, allowing the same compound to address multiple conditions (Alzheimer's, Parkinson's, cancer, viral infections) through common autophagy mechanisms while potentially adapting to disease-specific requirements through structural variations.
Data Source
AI summary
The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, and in particular neurological and/or CNS-related diseases. The present invention relates to compounds according to Formula (I) or salts, solvates and/or hydrates thereof, wherein said compounds induce and/or stimulate the process of autophagy, as well as uses of the compounds in the treatment and prevention of autophagy related diseases and disorders. Examples are cancer, age-related diseases, and viral infection, in particular of the CNS.